progesterone 11-hemisuccinate: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 5289373 |
CHEBI ID | 45496 |
SCHEMBL ID | 2781992 |
MeSH ID | M0318773 |
Synonym |
---|
progesterone-11-alpha-ol-hemisuccinate |
progesterone 11-hemisuccinate |
DB08547 |
4-[[(8s,9s,10r,11r,13s,14s,17s)-17-acetyl-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-11-yl]oxy]-4-oxobutanoic acid |
CHEBI:45496 , |
11alpha-hydroxyprogesterone succinate |
4-{[(11alpha)-3,20-dioxopregn-4-en-11-yl]oxy}-4-oxobutanoic acid |
p4-11alpha-hemisuccinate |
progesterone-11alpha-hemisuccinate |
11alpha-hydroxy-4-pregnene-3,20-dione-11-hemisuccinate |
p4-11alpha-hs |
11alpha-hemisuccinylprogesterone |
progesterone-11alpha-succinyl. |
EPITOPE ID:174331 |
SCHEMBL2781992 |
41238-98-6 |
11-alpha-hydroxy-4-pregnene-3,20-dione 11-hemisuccinate |
4-{[(8alpha,11beta,14beta,17alpha)-3,20-dioxopregn-4-en-11-yl]oxy}-4-oxobutanoic acid |
Q27097747 |
Class | Description |
---|---|
20-oxo steroid | An oxo steroid carrying an oxo group at position 20. |
dicarboxylic acid monoester | A monoester of a dicarboxylic acid. |
steroid ester | |
3-oxo-Delta(4) steroid | A 3-oxo steroid conjugated to a C=C double bond at the alpha,beta position. |
hemisuccinate | A succinate ester in which only one of the carboxy groups of succinic acid has been esterified. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 10 (66.67) | 18.7374 |
1990's | 4 (26.67) | 18.2507 |
2000's | 1 (6.67) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.10) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 18 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |